NCT04115306
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
Active, Not Recruiting
PHASE1Ages 18+InterventionalTreatmentPhoenix Molecular Designs
~61 participants
Updated 2026-07-16 on ClinicalTrials.gov
What's tested:PMD-026fulvestrant
At a glance
Recruiting sites
0 of 10 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and tolerability of PMD-026 in combination with fulvestrant in patients with HR+/HER2- previously treated breast cancer
Measured over 6 weeks
Conditions
Where it's being run
10 sites across 8 statesCalifornia3
Arizona1
Florida1
Illinois1
Massachusetts1
Michigan1
Ohio1
Texas1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
RSK2 positive from available archival or fresh tumor tissue (FFPE).
Histologically or cytologically diagnosed HR+, HER2-
ESR1 wild type
Diagnosis of adenocarcinoma of the breast with evidence of either locally advanced disease not amendable to resection or radiation with curative intent or metastatic disease not amendable to curative therapy
Must be appropriate candidates for endocrine therapy
Previously received at least 1 line of endocrine therapy for MBC or had recurrence while on adjuvant endocrine therapy for locally advanced breast cancer
Discontinued endocrine therapy at least 15 days prior to first dose of PMD-026
At least 1 measurable target lesion as defined by RECIST v1.1
Progression on or after treatment with a CDK4/6 inhibitor in combination with endocrine therapy inhibitor in the locally advanced or metastatic setting
Adequate hematologic, hepatic, and renal function as assessed by laboratory parameters
Toxicity related to prior therapy resolved to at least Grade 1 (alopecia excepted) or to at least Grade 2 with prior approval of the Medical Monitor
Exclusion
Prior chemotherapy
ESR1 mutations
≤14 days from biological or investigational therapy
Presence of visceral crisis or uncontrolled visceral disease for which chemotherapy would be indicated
Central nervous system metastases, unless appropriately treated and neurologically stable
History of leptomeningeal metastases
Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Known hepatitis B or hepatitis C infection
Known HIV-positive with CD4+ cell counts \<350 cells/μL
Known HIV-positive with a history of an AIDS-defining opportunistic infection
History of clinically significant cardiovascular abnormalities, including QTcF interval \>460 msec (using Fridericia's formula)
What this trial measures
- Safety and tolerability of PMD-026 in combination with fulvestrant in patients with HR+/HER2- previously treated breast cancer6 weeks
Incidence of AEs, DLTs, SAEs. Changes in laboratory, vital signs, and ECG values.